ARTICLE | Clinical News
OGX-427: Phase II start
April 15, 2013 7:00 AM UTC
By the end of the quarter, OncoGenex said that the Sarah Cannon Research Institute will begin the double-blind, placebo-controlled, U.S. Phase II Spruce trial to compare IV OGX-427 plus carboplatin an...